Endogenous neuroprotectants effects

Table 9.2 Effects of endogenous neuroprotectants (ganglioside, lipoic acid, and vitamin E) in neurological disorders...

Endogenous neuroprotectant Neurological disorder Therapeutic effect Reference... 

These observations led us to hypothesize that administration of BEO could have a neuroprotective effect against ischemic neuronal injury and that neuroprotection by BEO may stem from maintenance in the active state of endogenous survival programs only transiently activated in the ischemic penumbra. Given that BEO for systemic (intraperitoneal, i.p.) administration crosses the blood-brain barrier (BBB) in rat (Morrone et al, 2007), we considered this of special interest in view of the poor penetration into the brain of a number of neuroprotectants (Wu, 2005). 

An example of a MAO-B inhibitor is selegiline, which is used in combination with levodopa. The dose of levodopa can be reduced and there is evidence that this combination has a neuroprotective effect and slows the progression of the disease. This may be because in Parkinson s disease, MAO-B is involved in the production of an endogenous neurotoxin. Combination therapy with levodopa also reduces end of dose deterioration. 

Fowler CJ (2003) Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents non-psychoactive cannabinoids, entourage compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid psychotropic effects. Brain Res Rev 41 26-43... 

---